Revised prices of 1,364 anti-cancer formulations take effect in India

Revised maximum retail prices for 1,364 anti-cancer formulations came into effect on 9 November 2026. The National Pharmaceutical Pricing Authority, under the Department of Pharmaceuticals, capped trade margins on 137 anti-cancer drugs, based on recommendations from an Expert Committee set up by the Directorate General of Health Services on 17 October 2026. As of 8 November, 85 pharmaceutical companies had reported revised MRPs for 1,364 formulations covering 121 drugs. The ministry said 679 brands recorded reductions above 50 per cent.

The ministry called the measure part of its efforts to improve affordability and access to essential anti-cancer medicines. For hospital pharmacies, the revised MRP is the ceiling on what may be charged. Pricing complaints can be lodged through the Pharma Jan Samadhan portal or the NPPA helpline at 1800-111-255.